AGX-201
pharmaceutical compound
AGX-201, also known as histamine dihydrochloride, is a histamine receptor modulator which is under development for the treatment of migraine. It is or was also under development for a variety of other indications. The drug is given by subcutaneous injection.
It is the dihydrochloride salt of histamine. However, whereas histamine is said to efficiently induce migraine in people with migraine most likely via histamine H1 and H3 receptors, AGX-201 is said to act as an antagonist of the H1 receptor and as an agonist of the H3 receptor. This in turn is said to produce antimigraine effects by reducing the release of pro-inflammatory mediators in trigeminal nerve endings and hence via anti-inflammatory effects. The drug is also specifically said to modulate histamine receptors on mast cells to make them more resilient to degranulation as part of its antimigraine activity. The exact mechanism of action of AGX-201 in terms of its antimigraine effects is unknown however. The elimination half-life of histamine dihydrochloride by subcutaneous injection in humans is 14 to 61 minutes.
AGX-201 is under development by AgoneX Biopharmaceuticals.
The public source identifies “AGX-201” as pharmaceutical compound. This brief keeps that definition visible, then builds a research path around AGX-201, pharmaceutical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “AGX-201”, the useful work is to connect “pharmaceutical compound” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated May 31, 2026. The linked authority identifier is Q140244435. None of the 0 selected statements returned an explicit reference.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “AGX-201”, its source revision and the description used here.
- Expand the search: follow AGX-201 primary sources, AGX-201 archive and AGX-201 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “AGX-201”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “AGX-201” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.